{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-017799","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2026-05-19T20:45:23+00:00","discovered_at":"2026-05-19T20:46:00.291318+00:00","generated_at":"2026-05-19T20:48:46.526689+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eton Pharmaceuticals secures U.S. commercialization rights to IMPAVIDO® for $4.25M fixed fees","bullets":["Eton will pay $4.25M in fixed fees ($125k Jul 2026, then $1.25M Apr 2027, etc.) plus up to $4M in milestone payments based on cumulative net sales.","Royalty rates: 55% of net sales up to $7M/year, 50% above $7M/year; Supplier covers product costs and regulatory, Eton covers sales and marketing.","Exclusive U.S. commercialization rights start September 26, 2026; IMPAVIDO® had 2025 U.S. sales of $8.1M (Symphony Health).","IMPAVIDO® is the first FDA-approved oral therapy for leishmaniasis (visceral, cutaneous, mucosal), a rare parasitic disease.","This expands Eton's rare disease portfolio to eleven commercial products (including ten prior)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-017799","json":"https://secwatch.observer/filing/0001437749-26-017799.json","markdown":"https://secwatch.observer/filing/0001437749-26-017799.md","text":"https://secwatch.observer/filing/0001437749-26-017799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926017799/0001437749-26-017799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926017799/eton20260518_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T20:48:46.526689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"369ed65dc1f6c00e0a316c1bb219c97ad6474d6b","claim":"Eton Pharmaceuticals, Inc. entered into Supply and Distribution Agreement for IMPAVIDO® with affiliate of Knight Therapeutics, Inc. valued at $4.25 million fixed fees plus up to $4.0 million sales milestones and 55%/50% net sales share (effective 2026-05-18).","evidence_excerpt":"On May 18, 2026, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO® (miltefosine) oral capsules with an affiliate of Knight Therapeutics, Inc. (“Supplier”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926017799/0001437749-26-017799-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"affiliate of Knight Therapeutics, Inc."},{"label":"Value","value":"$4.25 million fixed fees plus up to $4.0 million sales milestones and 55%/50% net sales share"},{"label":"Effective","value":"2026-05-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}